Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Purchased by Wells Fargo & Company MN

Wells Fargo & Company MN raised its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 27.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 45,391 shares of the company’s stock after purchasing an additional 9,865 shares during the quarter. Wells Fargo & Company MN’s holdings in Atea Pharmaceuticals were worth $152,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. lifted its holdings in shares of Atea Pharmaceuticals by 1.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 659,527 shares of the company’s stock worth $2,209,000 after acquiring an additional 9,370 shares during the last quarter. Intech Investment Management LLC lifted its stake in Atea Pharmaceuticals by 236.0% during the fourth quarter. Intech Investment Management LLC now owns 35,989 shares of the company’s stock worth $121,000 after purchasing an additional 25,278 shares in the last quarter. CM Management LLC boosted its position in shares of Atea Pharmaceuticals by 11.1% during the fourth quarter. CM Management LLC now owns 300,000 shares of the company’s stock worth $1,005,000 after buying an additional 30,000 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Atea Pharmaceuticals by 72.9% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 76,352 shares of the company’s stock valued at $256,000 after buying an additional 32,195 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Atea Pharmaceuticals by 106.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 95,244 shares of the company’s stock valued at $319,000 after buying an additional 49,028 shares during the period. Hedge funds and other institutional investors own 86.67% of the company’s stock.

Atea Pharmaceuticals Trading Down 1.4 %

Shares of NASDAQ AVIR opened at $2.72 on Friday. Atea Pharmaceuticals, Inc. has a 12-month low of $2.60 and a 12-month high of $4.15. The stock has a market cap of $232.77 million, a P/E ratio of -1.31 and a beta of 0.17. The business’s fifty day simple moving average is $2.93 and its 200-day simple moving average is $3.12.

Atea Pharmaceuticals (NASDAQ:AVIR) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). On average, equities analysts forecast that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AVIR. Morgan Stanley lowered their target price on Atea Pharmaceuticals from $6.20 to $6.00 and set an “equal weight” rating for the company in a report on Friday, April 11th. William Blair reissued an “outperform” rating on shares of Atea Pharmaceuticals in a research note on Friday, March 7th.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.